In India, approximately 69 million patients are living with diabetes, and this number is expected to rise to 123.5 million by 2040.
With low levels of diabetes awareness and diagnosis, treating physicians have been shouldering much of the burden of educating the public with little support from other stakeholders such as the media, advocacy organizations and government bodies. As a result, more than half of patients with diabetes remain undiagnosed. And for those that are diagnosed, adherence to prescribed therapy remains low.
With an objective to increase public awareness of type-2 diabetes mellitus (T2DM) and to help existing patients take control of their disease, the Novartis Indian Metabolics team launched the patient support program (PSP), Prayaas (the Hindi word for ‘endeavor’).
As a key part of Prayaas, the team, in collaboration with healthcare practitioners, held a series of health camps where people were invited to get tested for T2DM using a simple blood test. Today, there are roughly 100 camps per month diagnosing over 2,000 patients per month.
The team is also working with state governments to provide additional diagnostic facilities in government hospitals. The program has established itself as the flagship diabetes PSP across Asia, the Middle East and Africa.
With the evolution of patient behavior, such as increased adoption of digital technology and requirement of personalized disease management, it was clear the team needed to reach patients where they were - online.
Based on the feedback received from patients, the Novartis Indian Metabolics team revamped the PSP with a major focus on digital through three solutions:
Since the inception of the program, over 50,000 patients have enrolled. The compliance to therapy ratio among patients enrolled in the program is now 9 months versus just 3 months for the average T2DM patient. The team, in partnership with the communities of India, are making a meaningful difference in the lives of T2DM patients in India, and have established themselves as a trusted partner among both patients and health care providers. Building on this strong foundation, and equipped with the new and improved PSP, the Novartis Indian Metabolics team is poised to make an even greater impact on Indian T2DM patients’ lives in the years to come.
To learn more about the Novartis Indian Metabolic team’s patient support program, explore their site.